Literature DB >> 1378350

Distribution of clusterin in Alzheimer brain tissue.

P L McGeer1, T Kawamata, D G Walker.   

Abstract

The immunohistochemical distribution of clusterin (SP40,40, SGP-2) was determined in Alzheimer disease (AD) and normal human brain tissue and compared with the distributions of vitronectin, protectin and the complement membrane attack complex (MAC). Antibodies to all four proteins showed staining of dystrophic neurites and neuropil threads in AD tissue, and residual serum in normal tissue, but only antibodies to clusterin and vitronectin strongly stained amyloid deposits in senile plaques. The clusterin antibody also showed punctate staining of some normal appearing AD pyramidal neurons, and very scattered staining of intracellular neurofibrillary tangles. Clusterin, vitronectin and protectin are all believed to inhibit membrane insertion by the MAC, and these data are consistent with upregulation of all three proteins in response to MAC formation in AD, and with a neuronal origin of clusterin.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1378350     DOI: 10.1016/0006-8993(92)90071-g

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  46 in total

Review 1.  Roles of the complement system in human neurodegenerative disorders: pro-inflammatory and tissue remodeling activities.

Authors:  Philippe Gasque; Jim W Neal; Sim K Singhrao; Eamon P McGreal; Yann D Dean; Beek Johan Van; B Paul Morgan
Journal:  Mol Neurobiol       Date:  2002-02       Impact factor: 5.590

2.  Regulation of an inactivating potassium current (IA) by the extracellular matrix protein vitronectin in embryonic mouse hippocampal neurones.

Authors:  Dmitry V Vasilyev; Michael E Barish
Journal:  J Physiol       Date:  2003-01-24       Impact factor: 5.182

3.  V-src-induced-transcription of the avian clusterin gene.

Authors:  Y Herault; G Chatelain; G Brun; D Michel
Journal:  Nucleic Acids Res       Date:  1992-12-11       Impact factor: 16.971

4.  Immunization targeting a minor plaque constituent clears β-amyloid and rescues behavioral deficits in an Alzheimer's disease mouse model.

Authors:  Jose Morales-Corraliza; Stephen D Schmidt; Matthew J Mazzella; Jason D Berger; Donald A Wilson; Daniel W Wesson; Mathias Jucker; Efrat Levy; Ralph A Nixon; Paul M Mathews
Journal:  Neurobiol Aging       Date:  2012-05-18       Impact factor: 4.673

Review 5.  Cell loss in retinal dystrophies by apoptosis--death by informed consent!

Authors:  C Y Gregory; A C Bird
Journal:  Br J Ophthalmol       Date:  1995-02       Impact factor: 4.638

6.  Do nonsteroidal anti-inflammatory drugs have a protective effect against dementia?

Authors:  F L Van Muiswinkel; P Eikelenboom
Journal:  Drugs Aging       Date:  1996-07       Impact factor: 3.923

7.  Genetic variability in CLU and its association with Alzheimer's disease.

Authors:  Rita J Guerreiro; John Beck; J Raphael Gibbs; Isabel Santana; Martin N Rossor; Jonathan M Schott; Michael A Nalls; Helena Ribeiro; Beatriz Santiago; Nick C Fox; Catarina Oliveira; John Collinge; Simon Mead; Andrew Singleton; John Hardy
Journal:  PLoS One       Date:  2010-03-03       Impact factor: 3.240

8.  The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex.

Authors:  J Ghiso; E Matsubara; A Koudinov; N H Choi-Miura; M Tomita; T Wisniewski; B Frangione
Journal:  Biochem J       Date:  1993-07-01       Impact factor: 3.857

9.  Downstream targets of methyl CpG binding protein 2 and their abnormal expression in the frontal cortex of the human Rett syndrome brain.

Authors:  Joanne H Gibson; Barry Slobedman; Harikrishnan K N; Sarah L Williamson; Dimitri Minchenko; Assam El-Osta; Joshua L Stern; John Christodoulou
Journal:  BMC Neurosci       Date:  2010-04-26       Impact factor: 3.288

10.  Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease.

Authors:  Denise Harold; Richard Abraham; Paul Hollingworth; Rebecca Sims; Amy Gerrish; Marian L Hamshere; Jaspreet Singh Pahwa; Valentina Moskvina; Kimberley Dowzell; Amy Williams; Nicola Jones; Charlene Thomas; Alexandra Stretton; Angharad R Morgan; Simon Lovestone; John Powell; Petroula Proitsi; Michelle K Lupton; Carol Brayne; David C Rubinsztein; Michael Gill; Brian Lawlor; Aoibhinn Lynch; Kevin Morgan; Kristelle S Brown; Peter A Passmore; David Craig; Bernadette McGuinness; Stephen Todd; Clive Holmes; David Mann; A David Smith; Seth Love; Patrick G Kehoe; John Hardy; Simon Mead; Nick Fox; Martin Rossor; John Collinge; Wolfgang Maier; Frank Jessen; Britta Schürmann; Reinhard Heun; Hendrik van den Bussche; Isabella Heuser; Johannes Kornhuber; Jens Wiltfang; Martin Dichgans; Lutz Frölich; Harald Hampel; Michael Hüll; Dan Rujescu; Alison M Goate; John S K Kauwe; Carlos Cruchaga; Petra Nowotny; John C Morris; Kevin Mayo; Kristel Sleegers; Karolien Bettens; Sebastiaan Engelborghs; Peter P De Deyn; Christine Van Broeckhoven; Gill Livingston; Nicholas J Bass; Hugh Gurling; Andrew McQuillin; Rhian Gwilliam; Panagiotis Deloukas; Ammar Al-Chalabi; Christopher E Shaw; Magda Tsolaki; Andrew B Singleton; Rita Guerreiro; Thomas W Mühleisen; Markus M Nöthen; Susanne Moebus; Karl-Heinz Jöckel; Norman Klopp; H-Erich Wichmann; Minerva M Carrasquillo; V Shane Pankratz; Steven G Younkin; Peter A Holmans; Michael O'Donovan; Michael J Owen; Julie Williams
Journal:  Nat Genet       Date:  2009-09-06       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.